In silico modeling and simulation techniques such as physiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics modeling (PBBM) have demonstrated various applications in drug discovery and development.
PBBM Considerations for Base Models, Model Validation, and Application Steps: Workshop Summary Report
The proceedings from the 30th August 2023 (Day 2) of the workshop “Physiologically Based Biopharmaceutics Models (PBBM) Best Practices for Drug Product Quality: Regulatory and Industry Perspectives” are provided herein.
Preparation and Evaluation of Nanolipid Carriers of Bedaquiline- In vitro Evaluation and in silico Prediction
Bedaquiline, a potent antitubercular drug used in the treatment of multidrug-resistant strains, suffers from low oral bioavailability, a slow onset of therapeutic action, and side effects.
Synthesis, Absolute Configuration, Biological Profile and Antiproliferative Activity of New 3,5-Disubstituted Hydantoins
Hydantoins, a class of five-membered heterocyclic compounds, exhibit diverse biological activities.
Advancing the Harmonization of Biopredictive Methodologies through the Product Quality Research Institute (PQRI) Consortium: Biopredictive Dissolution of Dipyridamole Tablets
Biorelevant dissolution and its concept have been widely accepted and further developed to meaningfully predict the bioperformance of oral drug products.
Effect of Data Quality and Data Quantity on the Estimation of Intrinsic Solubility: Analysis Based on a Single-Source Data Set
Aqueous solubility is one of the most important physicochemical properties of drug molecules and a major driving force for oral drug absorption.
Phase I Clinical Trial of NH130 and the Prediction of its Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling
Parkinson’s disease psychosis (PDP) is a common and distressing complication of Parkinson’s disease (PD), characterized by hallucinations and delusions.
In Silico Dose Adjustment of Zolpidem in Females Using Physiologically Based Pharmacokinetic Modeling and Simulations
Zolpidem (ZPD) is a non-benzodiazepine sedative indicated for the treatment of insomnia.
CFD-PK model for nasal suspension sprays: Validation with human adult in vivo data for triamcinolone acetonide
The objectives of this study were to expand and implement a Computational Fluid Dynamics (CFD)-Dissolution, Absorption and Clearance (DAC)-Pharmacokinetics (PK) multi-physics modeling framework for simulating the transport of suspension-based nasal corticosteroid sprays.
Application of Virtual Drug Study to New Drug Research and Development: Challenges and Opportunity
In recent years, virtual drug study, as an emerging research strategy, has become increasingly important in guiding and promoting new drug research and development.
PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management
This study aimed to model the pharmacokinetics of lamotrigine (LTG) and efavirenz (EFV) in pregnant women using physiologically based pharmacokinetic (PBPK) and pregnancy-specific PBPK (p-PBPK) models.
Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling
Omaveloxolone is a nuclear factor (erythroid-derived 2)-like 2 activator approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years, with a recommended dosage of 150 mg orally once daily on an empty stomach.
Mathematical Models of Ocular Drug Delivery
Drug delivery is an important factor for the success of ocular drug treatment.
Optimization of wet granulation process for manufacturing Rivaroxban generic immediate-release tablets using PBPK modeling and simulations
Granulation is the critical process for the pharmaceutical development of poorly water-soluble drug products.
A Semi-Mechanistic Physiologically Based Biopharmaceutics Model to Describe Complex and Saturable Absorption of Metformin: Justification of Dissolution Specifications for Extended Release Formulation
Physiologically based pharmacokinetic (PBPK) or physiologically based biopharmaceutics models (PBBM) demonstrated plethora of applications in both new drugs and generic product development.
Novel omeprazole delayed release orally disintegrating tablets for enhanced patient compliance: a case of model informed formulation development
The advanced in silico simulation tools, such as physiologically based biopharmaceutics models (PBBM) or physiologically based pharmacokinetic models (PBPK), play critical role in model informed formulation development.
A Physiologically Based Pharmacokinetic Model of Voriconazole in Human CNS —— Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Possible Transporter Mechanisms
Voriconazole is a classical antifungal drug that is often used to treat CNS fungal infections due to its permeability through the BBB.
Design and Evaluation of 3-Phenyloxetane Derivative Agonists of the Glucagon-Like Peptide-1 Receptor
Various small molecule GLP1R agonists have been developed and tested for treating type 2 diabetes (T2DM) and obesity.
Comparison of drug-induced liver injury risk between propylthiouracil and methimazole: A quantitative systems toxicology approach
Propylthiouracil (PTU) and methimazole (MMI), two classical antithyroid agents possess risk of drug-induced liver injury (DILI) with unknown mechanism of action.
Redefining Statin Dosage Post-Gastric Bypass: Insights from a Population Pharmacokinetics–Pharmacodynamics Link Approach
Roux-en-Y gastric bypass (RYGB) involves creating a small stomach pouch, bypassing part of the small intestine, and rerouting the digestive tract.